Successful Treatment for a Patient with Antiphospholipid Syndrome and Decreased Protein S Activity Exacerbated by Heparin-induced Thrombocytopenia: A Case Report

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2024 Nov 13

PMID 39533629

Authors

Masahiro Nishihara

Hiroto Nagae

Shimon Otake

Shinya Asatani

Yosuke Nagasawa

Kumiko Akiya

Hirotake Inomata

Noboru Kitamura

Hideki Nakamura

Affiliations

Soon will be listed here.

Abstract

Rationale: Antiphospholipid antibody syndrome and protein S/C deficiency are diseases that are sometimes complicated by thrombus, and heparin-induced thrombosis (HIT) has also been reported.

Patient Concerns: A male patient in his 60s with elevated D-dimer and superior mesenteric thrombus and portal vein thrombus underwent partial small intestine resection and thrombectomy. After administration of heparin, aortic thrombosis and pulmonary embolism occurred along with rapid thrombocytopenia.

Diagnosis: The patient was diagnosed with HIT combined with protein S deficiency and antiphospholipid antibody syndrome.

Interventions And Outcomes: Heparin administration was discontinued, and plasma exchange with fresh frozen plasma replacement and argatroban administration were started. These treatments reduced D-dimer, restored platelet counts, and improved thrombosis.

Lessons: Although HIT alone can cause severe arteriovenous thrombosis, our case suggests that it is important to search for the underlying procoagulant factors.

References

Hoppensteadt D, Walenga J . The relationship between the antiphospholipid syndrome and heparin-induced thrombocytopenia. Hematol Oncol Clin North Am. 2008; 22(1):1-18, v. DOI: 10.1016/j.hoc.2007.11.001. View

Adediran S, Agostino N . Coexistence of Antiphospholipid Syndrome and Heparin-Induced Thrombocytopenia in a Patient with Recurrent Venous Thromboembolism. Case Rep Hematol. 2017; 2017:3423548. PMC: 5424171. DOI: 10.1155/2017/3423548. View

Alhanshani A . Heparin Induced Thrombocytopenia - Pathophysiology, Diagnosis and Treatment: A Narrative Review. Int J Gen Med. 2023; 16:3947-3953. PMC: 10475297. DOI: 10.2147/IJGM.S420327. View

Denton M, Mauiyyedi S, Bazari H . Heparin-induced skin necrosis in a patient with end-stage renal failure and functional protein S deficiency. Am J Nephrol. 2001; 21(4):289-93. DOI: 10.1159/000046263. View

Diz-Kucukkaya R, Hancer V, Artim-Esen B, Pekcelen Y, Inanc M . The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome. J Thromb Thrombolysis. 2009; 29(3):303-9. DOI: 10.1007/s11239-009-0356-9. View

Todorova M, Baleva M . Some recent insights into the prothrombogenic mechanisms of antiphospholipid antibodies. Curr Med Chem. 2007; 14(7):811-26. DOI: 10.2174/092986707780090945. View

Ginsberg J, Demers C, Brill-Edwards P, Bona R, Johnston M, Wong A . Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus. Am J Med. 1995; 98(4):379-83. DOI: 10.1016/S0002-9343(99)80317-9. View

Adachi T . Protein S and congenital protein S deficiency: the most frequent congenital thrombophilia in Japanese. Curr Drug Targets. 2005; 6(5):585-92. DOI: 10.2174/1389450054545980. View

Beckmann L, Voigtlaender M, Holstein K, Lennartz M, Schneider S, Haddad M . Monocyte activation and acquired autoimmune protein S deficiency promote disseminated intravascular coagulation in a patient with primary antiphospholipid syndrome. Res Pract Thromb Haemost. 2021; 5(5):e12559. PMC: 8265818. DOI: 10.1002/rth2.12559. View

10.

Majumder R, Nguyen T . Protein S: function, regulation, and clinical perspectives. Curr Opin Hematol. 2021; 28(5):339-344. PMC: 8373800. DOI: 10.1097/MOH.0000000000000663. View

11.

Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson C, Ketterling R . Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J. 2017; 7(12):662. PMC: 5802551. DOI: 10.1038/s41408-017-0035-6. View

12.

Siddiq B, DeJong M, Decicco E, Zielke T, DAndrea M, Aulivola B . Extent of mural thrombus is not associated with increased 5-year mortality following elective AAA repair. Vascular. 2022; 31(2):219-225. DOI: 10.1177/17085381211063282. View

13.

Crowther M, Johnston M, Weitz J, Ginsberg J . Free protein S deficiency may be found in patients with antiphospholipid antibodies who do not have systemic lupus erythematosus. Thromb Haemost. 1996; 76(5):689-91. View

14.

Torn M, Cannegieter S, Bollen W, van der Meer F, van der Wall E, Rosendaal F . Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients. Arch Intern Med. 2009; 169(13):1203-9. DOI: 10.1001/archinternmed.2009.176. View

15.

Comp P, Esmon C . Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med. 1984; 311(24):1525-8. DOI: 10.1056/NEJM198412133112401. View

16.

Nguyen B, Morales Hernandez M, Baldeo C, Cury J, Ferreira J . A case-report of successful use of thromboelastography to manage anticoagulation therapy in a patient with concomitant catastrophic antiphospholipid syndrome and heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis. 2019; 30(4):171-175. DOI: 10.1097/MBC.0000000000000810. View

17.

Glueck C, Smith D, Gandhi N, Hemachandra K, Shah P, Wang P . Treatable high homocysteine alone or in concert with five other thrombophilias in 1014 patients with thrombotic events. Blood Coagul Fibrinolysis. 2015; 26(7):736-42. DOI: 10.1097/MBC.0000000000000276. View

18.

Patriarcheas V, Pikoulas A, Kostis M, Charpidou A, Dimakakos E . Heparin-induced Thrombocytopenia: Pathophysiology, Diagnosis and Management. Cureus. 2020; 12(3):e7385. PMC: 7179984. DOI: 10.7759/cureus.7385. View